At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
Vortioxetine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Placebo-Controlled Study of Vortioxetine in the Treatment of Binge Eating Disorder
In Brief
A Phase 2 clinical trial evaluating Vortioxetine and Placebo for Binge Eating Disorder. Completed, enrolled 80 participants across 1 site.
Detailed Summary
The aim of the present study is to examine the efficacy and safety of vortioxetine vs placebo in adults with moderate to severe Binge eating disorder, as indicated by at least 3 binge eating days per week for the 2 weeks before the baseline visit.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBinge Eating Disorder
CountriesUnited States
CollaboratorsTakeda
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 2015
Enrollment StartJun 2016
Primary CompletionNov 2018
TodayJul 2026
First PostedAug 19, 2015
Enrollment StartJun 1, 2016
Primary CompletionNov 1, 2018
TodayJul 1, 2026
Enrollment to primary: 2.4 yearsPosted 10.9 years ago
Interventions
Vortioxetinedrug
Medication currently approved for major depression.
Placebodrug